ClinicalTrials.gg
RecruitingNCT06559696Updated Oct 29, 2026

Internal Mammary Lymph Nodes Irradiation in High-risk Breast Cancer After Neoadjuvant Chemotherapy

A Phase 3 interventional study of internal mammary nodal irradiation and No internal mammary node irradiation in Breast Cancer, sponsored by Fujian Medical University Union Hospital. Recruiting at 1 site in China. Open to female participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Fujian Medical University Union Hospital · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
722
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Breast Neoplasms by Fujian Medical University Union Hospital — 4 open to participants now, 6 under way, 1 of them phase 3. Breast Neoplasms · Fujian Medical University Union Hospital.

Started
2024
with 2 others
Phase 3
Only one
of the 11
Registered
10th of 11
by date

Among the 11 studies in Breast Neoplasms by Fujian Medical University Union Hospital, this one is one of 3 that started in 2024, is the only one in phase 3, and was the 10th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

4 of the 11 studies in Breast Neoplasms by Fujian Medical University Union Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 75 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Breast Neoplasms by Fujian Medical University Union Hospital, or all of them as a file.
02

Study summary

The aim of this study is to explore the impact of internal mammary nodal irradiation on disease-free survival in high-risk breast cancer patients (ypN+or supra/subclavicular lymph node positive) after neoadjuvant chemotherapy.

Read the detailed description

This is a prospective, randomized phase 3 trial. Breast cancer patients with axillary lymph node-positive or supra/subclavicular lymph node metastasis underwent neoadjuvant chemotherapy were included. Patients underwent regional nodal irradiation along with breast or chest wall irradiation and randomly allocated to either IMNI or no IMNI.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Breast Cancer
  • Internal mammary nodal
  • Radiation
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed invasive breast cancer
  • Underwent chemotherapy
  • Performance Status Scale 0-2
  • ypN+ after neoadjuvant chemotherapy or supraclavicular/subclavicular lymph node before system therapy
  • No distant metastases
  • No internal mammary nodes metastases based on images before system therapy
  • Willing to follow up
  • Written,

Exclusion criteria

Exclusion Criteria:

  • Without chemotherapy
  • Distant
  • Simultaneous bilateral breast cancer
  • Pathological confirmation or imaging consideration of lymph node metastasis in the internal mammary before system therapy
  • Had simultaneous or previous secondary , except for non-malignant melanoma skin cancer, papillary thyroid / follicular carcinoma, cervical carcinoma in situ, contralateral non-invasive breast cancer
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
722 participants (estimated)

Study arms

  • Experimental
    internal mammary nodal irradiation

    chest wall/whole breast and supraclavicular+-axillary nodal plus internal mammary nodal irradiation

    Radiation: internal mammary nodal irradiation

  • Active comparator
    No internal mammary node irradiation

    chest wall/whole breast and supraclavicular+-axillary nodal irradiation

    Radiation: No internal mammary node irradiation

Interventions

  • Radiationinternal mammary nodal irradiation

    chest wall/whole breast and supraclavicular +-axillary plus internal mammary nodal irradiation (50 Gy in 25 fractions or 40Gy in 15 fractions).

  • RadiationNo internal mammary node irradiation

    chest wall/whole breast and supraclavicular +-axillary irradiation (50 Gy in 25 fractions or 40Gy in 15 fractions).

06

What researchers measure

Primary outcomes

  1. Disease free survival

    From date of enrollment until to the first recurrence in the ipsilateral breast or chestwall, the regional nodal area, or a distant site or death due to any cause

    Time frame: 5 years

Secondary outcomes

  1. Overall survival

    From date of enrollment until the date of death from any cause.

    Time frame: 5 years

  2. Distant metastasis-free survival

    The time of randomization to the first recurrence in a distant site.

    Time frame: 5 years

  3. Local-regional recurrence-free survival

    The time of randomization to the first recurrence in the ipsilateral breast or chest wall and the regional nodal area.

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Jul 2032, 96 months after the start.

Of 328 non-industry phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 127. This study's planned 96 months is above that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2024
First posted
Aug 19, 2024
StartActual
Jul 15, 2024
Primary completionEst.
Jul 15, 2032
CompletionEst.
Jul 15, 2032
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers, verification date, oversight details, index terms and contact details
2 updates, last Oct 29, 2026
Show all 2 updates
  1. Oct 29, 2026
    Minor edits only
    + 1 other change: contact details
  2. Oct 28, 2026
    Minor edits only
    + 4 other changes: identifiers, verification date, oversight details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06559696
Responsible party
Yong Yang (M.D., Fujian Medical University Union Hospital) — Principal investigator
First posted
Aug 19, 2024
Start date
Jul 15, 2024
Primary completion
Jul 15, 2032 (estimated)
Completion
Jul 15, 2032 (estimated)
Last update
Oct 29, 2026

Study contacts

Yong Yang, M.S
Contact
dr_yangyong1983@163.com
18813019084
Yong Yang, MD
principal investigator · Fujian Medical University Union Hospital
Jian Liu (jianliu@nankai.edu.cn), PhD
study director · Nankai University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion